Han Tun is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4500 San Pablo Rd S
Jacksonville, FL 322241865
Telephone
904-953-2000Provider last certified this registry record 31 Aug 2020.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20231 payment
- ADC Therapeutics America, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57.3%PD-1 inhibitor29.1%Pembrolizumab64%Nivolumab36%Part B, office-administered≥32 patientsMicrotubule Inhibitor13.1%Paclitaxel protein-bound particles54%Paclitaxel46%Part B, office-administered≥16 patients+ 8 more classes in this area
Metabolism & gastrointestinal
21.8%Other antiemetics17.4%Fosaprepitant100%Part B, office-administered≥45 patientsSerotonin-3 Receptor Antagonist3%Palonosetron hcl57%Ondansetron hydrochloride43%Part B, office-administered≥66 patients+ 4 more classes in this area
Blood & clotting
13.8%Erythropoiesis-stimulating Agent13.8%Darbepoetin alfa100%Part B, office-administered≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2012–2013 per NIH RePORTER. The latest:
- Osteopontin-mediated invasion and dissemination in central nervous system lymphom
Mayo Clinic Jacksonville
FY2013$186,969R21NS075509 - Osteopontin-mediated invasion and dissemination in central nervous system lymphom
Mayo Clinic Jacksonville
FY2012$232,500R21NS075509
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”